Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 10/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.46 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664486 | 0.90 | S1PR5 (0.56) | S1PR1S1PR5S1PR4S1PR3GRK5 | |
| SCHEMBL4662867 | 0.85 | S1PR5 (0.55) | S1PR1S1PR5S1PR4S1PR3GRK5 | |
| SCHEMBL16493532 | 0.85 | S1PR1 (0.45) | S1PR1S1PR5S1PR4S1PR3GRK5 | |
| SCHEMBL5851485 | 0.83 | S1PR1 (0.46) | S1PR1S1PR5S1PR4S1PR3GRK5 | |
| SCHEMBL16493516 | 0.80 | S1PR1 (0.44) | S1PR1S1PR5S1PR4S1PR3GRK5 | |
| SCHEMBL4664711 | 0.80 | EGFR (0.47) | S1PR1 | |
| SCHEMBL4792489 | 0.79 | S1PR1 (0.47) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL4663091 | 0.78 | S1PR5 (0.53) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL13271331 | 0.77 | S1PR5 (0.58) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL4662864 | 0.76 | KIF11 (0.44) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638551-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2011-12-21 | — | — | EP | disclosed |
| EP-1638551-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7060697-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-06-13 | — | — | US | disclosed |
| EP-1638551-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-29 | — | — | EP | disclosed |
| US-20050014724-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004103309-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014724-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR5 70/4885S1PR4 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.